COMPUTATIONAL TECHNOLOGIES AVAILABLE TO THE DRUG DISCOVERY INDUSTRY TODAY CAN OFTEN WORK FOR NUMEROUS TARGETS , REGARDLESS OF THE DISEASE OR THE NATURE OF THE TARGET ITSELF .
D I G I T A L D I A G N O S T I C S
COMPUTATIONAL TECHNOLOGIES AVAILABLE TO THE DRUG DISCOVERY INDUSTRY TODAY CAN OFTEN WORK FOR NUMEROUS TARGETS , REGARDLESS OF THE DISEASE OR THE NATURE OF THE TARGET ITSELF .
animal models . Our expertise also extends to important and lethal infections , including those related to Cystic Fibrosis .
As we enter the next stage of our growth , we are conducting an important fundraising exercise and plan to expand our AI-enabled pipeline to address even more diseases with unmet need using our advanced computational and biochemical expertise .
These may include major current areas of medical interest such as healthy ageing and further specific applications in oncology where it has been difficult to find effective treatments .
Using SynthAI one can start designing a new drug based on a specific target , while in other contexts the search begins with an active molecule and then one seeks to discover what target it could be most effective for .
Today ’ s SynthAI technology can approach the discovery process from either direction , and we ’ ve proven that it works effectively in both scenarios , in particular with our own work on oncology and resistant infections .
At Oxford Drug Design we are currently focused on oncology , working against various types of tumours where our drug candidates have already shown promising results in
The key though is that an innovative drug discovery company like Oxford Drug Design can deploy its distinctive biochemical target expertise to accompany our computational capability thus enabling our expansion into seemingly unrelated disease areas which in our hands do share a common thread .
In our work this thread is the world-class understanding of tRNA synthetases , an enzyme family on which Oxford Drug Design has developed a deep understanding , and which can connect diseases including inflammation , degenerative kidney disorders and others .
While it ’ s difficult to accurately predict how many years AI will ultimately reduce the time it takes to develop a drug or any medical approach , one thing is certain : the overall process of reaching effective , safer drugs is gradually accelerating . In 2025 , this heightened accuracy and speed of progression is what we expect to see . �
www . intelligenthealth . tech 65